ReviewCell communication and signaling : CCS2026
Intratumoral microbiota and metabolites: dual roles in cancer progression and therapeutic opportunities.
Review in Cell communication and signaling : CCS, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- On the Edge of Benefit and Harm: Reactive Oxygen Species in Cancer.International journal of molecular sciences · 2026Review
- Reconsidering immunotherapy resistance: the emerging role of the tumor microbiome in head and neck and lung cancers.Annals of medicine and surgery (2012) · 2026Article
- Programming the tumor microenvironment through microbiome-driven mechanisms.Frontiers in cellular and infection microbiology · 2026Review
- Global trends and emerging frontiers in cancer immunotherapy and gut microbiota-derived metabolites: a bibliometric analysis.Frontiers in cellular and infection microbiology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Microorganisms play critical roles in tumor development, diagnosis, and treatment. In recent years, the newfound understanding of microorganisms in cancer tissues has sparked a renewed enthusiasm and research interest. The intratumoral microbes and metabolites have been discovered to interact with tumor cells to exert tumor-promoting or tumor-suppressing effects. Intratumoral microorganisms and their metabolites can alter tumor metabolism, activate key signaling pathways, regulate anti-tumor immunity, and affect tumor metastasis or recurrence. Additionally, intratumoral microbiota has emerged as promising predictive biomarkers for both diagnosis and prognosis of cancer patients. Intratumoral microorganisms and metabolites also have a substantial impact on tumor treatment by influencing therapeutic efficacies of immunotherapy, chemotherapy and radiotherapy. Intratumoral microbes can also serve as carriers to transport anti-tumor drugs, directly modulating intratumoral microecology and intervening in the carcinogenic pathway. However, the current research on the understanding of intratumoral microbiome and their metabolites is still limited and warrants more in-depth exploration. In this review, we extensively explore the structure and role of the intratumoral microbiota and metabolites in different cancer types, summarize the potential role in tumor diagnosis and prognosis, and provide recent advances of clinical implications for cancer treatment. (Source: Created with https://www.biorender.com/).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.